OINDPnews


H&T Presspart banner

Business

ARS raises $55 million for potential launch of its Neffy intranasal epinephrine

ARS Pharmaceuticals said that it has raised $55 million in a Series D financing round to support approval and potential launch of its Neffy (ARS-1) intranasal epinephrine for the treatment of anaphylaxis as well as studies of the nasal spray for other indications. ARS submitted an MAA for Neffy to the EMA in November 2020. The FDA granted Fast Track designation … [Read more...] about ARS raises $55 million for potential launch of its Neffy intranasal epinephrine

Lupin launches Luforbec beclometasone/formoterol MDI in the UK

Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June 2021. According to Lupin, the Luforbec inhaler will be manufactured at the company's facilities in the US and India. The company cited UK prescribing data … [Read more...] about Lupin launches Luforbec beclometasone/formoterol MDI in the UK

Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor

Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx's SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the … [Read more...] about Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor

Cellics partners with HCmed on delivery of inhaled nanosponges

Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the … [Read more...] about Cellics partners with HCmed on delivery of inhaled nanosponges

Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI

Aptar Pharma will have 12 months to decide whether to exercise an exclusive option to acquire worldwide rights to Pharmaxis's high payload Orbital dry powder inhaler under a new agreement, the company said. The Orbital DPI, which can deliver up to 400 mg of powder in divided doses, was designed for delivery of Pharmaxis's Bronchitol inhaled mannitol, and Pharmaxis … [Read more...] about Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI

Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye

Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma's OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes a $17.5 million upfront payment and up to $204.8 million in milestone payments and royalties. Earlier this year, Ji Xing acquired … [Read more...] about Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye

Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials

According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry of Health, Labour and Welfare approved Arikayce for that indication in March 2021. The company also … [Read more...] about Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials

NRx, MannKind partner on possible Zyesami aviptadil DPI

MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind's Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its facility in Danbury, CT, USA. TFF Pharmaceuticals had previously announced that it was conducting a feasibility study to … [Read more...] about NRx, MannKind partner on possible Zyesami aviptadil DPI